- Zacks•2 days ago
Ligand Pharmaceuticals Incorporated (LGND) said its partner Melinta Therapeutics, a private pharma company, has submitted New Drug Applications (NDAs) to the FDA for its pipeline candidate Baxdela (delafloxacin) to treat serious bacterial infections.
- Business Wire•3 days agoLigand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections
Ligand Pharmaceuticals Incorporated partner Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has submitted New Drug Applications to the U.S.
- Business Wire•14 days agoLigand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference
Ligand Pharmaceuticals Incorporated announced today plans to report third quarter 2016 financial results on November 3, 2016. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call.
Ligand Pharmaceuticals Incorporated (LGND)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||94.13 x 100|
|Ask||94.26 x 100|
|Day's Range||93.34 - 95.93|
|52wk Range||82.06 - 139.79|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||8.90|
|Avg Vol (3m)||417,733|
|Dividend & Yield||0.00 (0.00%)|